Cardiovascular disease (CVD) is the most frequent cause of death in nonalcoholic fatty liver disease (NAFLD). Insulin resistance, hepatic dysfunction, and chronic inflammation are factors interacting in explaining the increased CVD incidence in NAFLD. We aimed to evaluate the effects of insulin resistance and inflammatory biomarkers on asymmetric dimethylarginine (ADMA) levels, a predictor of CVD. We also investigated relationship between these markers and histological findings in patients with NAFLD.
Patients and Methods
Plasma ADMA, high-sensitivity C-reactive protein (hs-CRP), interleukin 6 (IL-6), and homeostasis model assessment of insulin resistance (HOMA-IR) were measured in 70 patients with histologically verified NAFLD (53 with nonalcoholic steatohepatitis [NASH], 17 with non-NASH) and 12 controls.
Results
The HOMA-IR (5.3 [3.9] vs 1.9 [1], P < 0.001), hs-CRP (5.6 [4.2] vs 2.2 [2.3] mg/L, P < 0.001), ADMA (0.81 [0.25] vs 0.48 [0.24] μmol/L, P = 0.005), and IL-6 (4.1 [1.2] vs 1.0 [0.4] pg/mL, P < 0.001) levels were all found higher in the NAFLD group than the control group. The ADMA levels were significantly higher in patients with NAFLD independent from HOMA-IR and body composition (P = 0.02). The IL-6 and HOMA-IR levels of the NASH group were found significantly higher than those of the non-NASH group. The only determinant significantly correlated to ADMA was HOMA-IR.
Conclusions
Our data suggested that although ADMA levels are independently higher in NAFLD, the only determinant correlated to ADMA is HOMA-IR and not inflammatory biomarkers (hs-CRP, IL-6) or presence/absence of NASH.
RafiqN, BaiC, FangY. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol. 2009; 7 (2): 234–238.
3.
OngJP, PittsA, YounossiZM.Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol. 2008; 49 (4): 608–612.
4.
SiervoM, CoranderM, StrangesS. Post-challenge hyperglycaemia, nitric oxide production and endothelial dysfunction: the putative role of asymmetric dimethylarginine (ADMA). Nutr Metab Cardiovasc Dis. 2011; 21 (1): 1–10.
5.
VallanceP, LeoneA, CalverA. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol. 1992; 20 (Suppl 12): S60–S62.
6.
BogerRH, Bode-BogerSM, SzubaA. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation. 1998; 98: 1842–1847.
7.
HorowitzJD, HeresztynT. An overview of plasma concentrations of asymmetric dimethylarginine (ADMA) in health and disease and in clinical studies: methodological considerations. J Chromatogr B Analyt Technol Biomed Life Sci. 2007; 851 (1–2): 42–50.
8.
KielsteinJT, BögerRH, Bode-BögerSM. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: Relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol. 1999; 10 (3): 594–600.
9.
WilsonAM, ShinDS, WeatherbyC. Asymmetric dimethylarginine correlates with measures of disease severity, major adverse cardiovascular events and all-cause mortality in patients with peripheral arterial disease. Vasc Med. 2010; 15 (4): 267–274.
10.
CavusogluE, RuwendeC, ChopraV. Relation of baseline plasma ADMA levels to cardiovascular morbidity and mortality at two years in men with diabetes mellitus referred for coronary angiography. Atherosclerosis. 2010; 210 (1): 226–231.
11.
SydowK, MondonCE, CookeJP. Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA. Vasc Med. 2005; 10 (Suppl 1): S35–S43.
12.
RichirMC, BouwmanRH, TeerlinkT. The prominent role of the liver in the elimination of asymmetric dimethylarginine (ADMA) and the consequences of impaired hepatic function. JPEN J Parenter Enteral Nutr. 2008; 32 (6): 613–621.
13.
TsikasD, RodeI, BeckerT. Elevated plasma and urine levels of ADMA and 15(S)-8-iso-PGF2alpha in end-stage liver disease. Hepatology. 2003; 38 (4): 1063–1064.
14.
AbbasiF, AsagmiT, CookeJP. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol. 2001; 88 (10): 1201–1203.
15.
AltinovaAE, ArslanM, Sepici-DincelA. Uncomplicated type 1 diabetes is associated with increased asymmetric dimethylarginine concentrations. J Clin Endocrinol Metab. 2007; 92 (5): 1881–1885.
16.
VidelaLA, RodrigoR, OrellanaM. Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients. Clin Sci (Lond). 2004; 106 (3): 261–268.
17.
WieckowskaA, PapouchadoBG, LiZ. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol. 2008; 103 (6): 1372–1379.
18.
ACE/ADA Task Force on Inpatient Diabetes. American College of Endocrinology and American Diabetes Association consensus statement on inpatient diabetes and glycemic control. Diabetes Care. 2006; 29 (8): 1955–1962.
19.
GrundySM, BrewerHBJr, CleemanJI. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004; 109 (3): 433–438.
20.
KleinerDE, BruntEM, Van NattaM. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41 (6): 1313–1321.
21.
VallanceP, LeoneA, CalverA. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 1992; 339 (8793): 572–575.
22.
SchnabelR, BlankenbergS, LubosE. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res. 2005; 97 (5): e53–e59.
23.
ZoccaliC, Bode-BögerS, MallamaciF. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet. 2001; 358 (9299): 2113–2117.
24.
BögerRH. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc Res. 2003; 59 (4): 824–833.
25.
ColakY, SenatesE, YesilA. Assessment of endothelial function in patients with nonalcoholic fatty liver disease. Endocrine. 2013; 43 (1): 100–107.
26.
KasumovT, EdmisonJM, DasarathyS. Plasma levels of asymmetric dimethylarginine in patients with biopsy-proven nonalcoholic fatty liver disease. Metabolism. 2011; 60 (6): 776–781.
27.
LluchP, TorondelB, MedinaP. Plasma concentrations of nitric oxide and asymmetric dimethylarginine in human alcoholic cirrhosis. J Hepatol. 2004; 41 (1): 55–59.
28.
VizzuttiF, RomanelliRG, ArenaU. ADMA correlates with portal pressure in patients with compensated cirrhosis. Eur J Clin Invest. 2007; 37 (6): 509–515.
29.
StuhlingerMC, AbbasiF, ChuJW. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA. 2002; 2877 (11): 1420–1426.
30.
ChanNN, ChanJC. Asymmetric dimethylarginine (ADMA): a potential link between endothelial dysfunction and cardiovascular diseases in insulin resistance syndrome?Diabetologia. 2002; 45 (12): 1609–1616.
31.
GarciaRG, PerezM, MaasR. Plasma concentrations of asymmetric dimethylarginine (ADMA) in metabolic syndrome. Int J Cardiol. 2007; 122 (2): 176–178.
32.
OnatA, HergençG, CanG. Serum asymmetric dimethylarginine levels among Turks: association with metabolic syndrome in women and tendency to decrease in smokers. Turk Kardiyol Dern Ars. 2008; 36 (1): 7–13.
33.
LundmanP, ErikssonMJ, StühlingerM. Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. J Am Coll Cardiol. 2001; 38 (1): 111–116.
34.
ItoA, TsaoPS, AdimoolamS. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation. 1999; 99 (24): 3092–3095.
35.
BögerRH, LentzSR, Bode-BögerSM. Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans. Clin Sci (Lond). 2001; 100 (2): 161–167.
36.
SurdackiA, NowickiM, SandmannJ. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol. 1999; 33 (4): 652–658.
37.
TripepiG, Mattace RasoF, SijbrandsE. Inflammation and asymmetric dimethylarginine for predicting death and cardiovascular events in ESRD patients. Clin J Am Soc Nephrol. 2011; 6 (7): 1714–1721.
38.
KuklaM, Zwirska-KorczalaK, HartlebM. Serum chemerin and vaspin in non-alcoholic fatty liver disease. Scand J Gastroenterol. 2010; 45 (2): 235–242.
